Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
117 hedge funds and large institutions have $1.62B invested in Centessa Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 34 reducing their positions, and 31 closing their positions.
322% more call options, than puts
Call options by funds: $8.54M | Put options by funds: $2.02M
32% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 34
1.31% less ownership
Funds ownership: 93.79% → 92.48% (-1.3%)
9% less funds holding
Funds holding: 129 → 117 (-12)
10% less capital invested
Capital invested by funds: $1.8B → $1.62B (-$174M)
29% less funds holding in top 10
Funds holding in top 10: 14 → 10 (-4)
39% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$18.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$15.5M |
| 4 |
Millennium Management
New York
|
+$13.3M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$32.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$24M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$22.2M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$17.6M |
| 5 |
Morgan Stanley
New York
|
-$14.5M |
CNTA Hedge Fund Activity: Q2 2025 in Review
117 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2025, worth a combined $1.62B — down 9.7% from $1.8B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of CNTA and 19 opened new positions — a net loss of 12 holders — while 34 trimmed existing stakes and 45 added.
The largest buyer was RTW Investments, adding an estimated $18.7M. The largest seller was Holocene Advisors, exiting entirely with an estimated $32.4M sold.
- 117 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2025, down from 129 in Q1 2025.
- Funds reported $1.62B of Centessa Pharmaceuticals stock for Q2 2025, down 9.7% quarter-over-quarter.
- 19 funds opened new Centessa Pharmaceuticals positions in Q2 2025 and 31 closed out, a net change of -12 holders.
- The largest Centessa Pharmaceuticals buyer in Q2 2025 was RTW Investments, an estimated $18.7M added.
- The largest Centessa Pharmaceuticals seller in Q2 2025 was Holocene Advisors, an estimated $32.4M sold.
Based on aggregated 13F filings for Q2 2025.